

Market Announcement

23 February 2022

Integral Diagnostics Limited (ASX: IDX) - Trading Halt

Description

The securities of Integral Diagnostics Limited ('IDX') will be placed in trading halt at the request of IDX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 25 February 2022 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)



Suite 9.02, Level 9, 45 William Street Melbourne Vic 3000

www.integraldiagnostics.com.au

23 February 2022

Melissa Kostopoulos Compliance Adviser, Listings Compliance (Melbourne) ASX Compliance Pty Ltd Level 4, North Tower, Rialto 525 Collins Street MELBOURNE VIC 3000

By Email

melissa.kostopoulos@asx.com.au tradinghaltsmelbourne@asx.com.au

Dear Melissa,

REQUEST FOR TRADING HALT

Integral Diagnostics Limited (ASX: IDX) (Company) requests that its securities be placed in a trading halt from the commencement of trading today pursuant to ASX Listing Rule 17.1.

The trading halt is requested pending an announcement by the Company in connection with an acquisition and a capital raising to be undertaken by way of a pro rata accelerated non-renounceable entitlement offer (Entitlement Offer).

The Company requests that the trading halt remain in place until the earlier of:

- 1. an announcement being made about the completion of the institutional component of the Entitlement Offer; or
- 2. the commencement of trading on Friday, 25 February 2022.

The Company is not aware of any reason why the trading halt should not be granted or any other information necessary to inform the market about the trading halt.

Please contact me if you require any additional information.

Yours sincerely

Kirsty Lally

Company Secretary Tel: +61 402 094 569

Showing Xall

Email: klally@idxgroup.com.au